Zevra Therapeutics, Inc. (ZVRA)
(Real Time Quote from BATS)
$11.44 USD
0.00 (0.00%)
Updated Aug 6, 2025 01:30 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZVRA 11.44 0.00(0.00%)
Will ZVRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZVRA
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Other News for ZVRA
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference | ZVRA ...
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call | ZVRA Stock News
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to ...
ZVRA: Zevra Therapeutics Seeks EMA Approval for NPC Drug Arimoclomol
Zevra Therapeutics submits MAA to EMA for evaluation of arimoclomol